Skip to main content
TipRanks
Go Ultimate75% OFF

Utah Medical Products (UTMD) AI Stock Analysis

123 Followers
UTMD

Utah Medical Products

(NASDAQ:UTMD)

Select Model
Rating:63Neutral
Price Target:$77.00â–²(6.91% Upside)
Action:downgraded
Date:11/14/26

The overall score of 63 reflects a company with a very strong financial foundation that is taking steps to address its core business challenge. The primary strength is the pristine balance sheet and high cash flow conversion, which provides safety and enabled the recent acquisition. The most significant risk has been the persistent decline in revenue, but the Orion Medical acquisition is a notable positive event that directly combats this trend and is the main driver for the score's upside. The neutral technical and valuation metrics have a moderating effect on the overall assessment.

Positive Factors
Balance Sheet StrengthMinimal leverage materially reduces financial risk and preserves flexibility to fund operations, acquisitions, dividends, or buybacks without a meaningful debt burden. Stable equity and healthy ROE further support resilience if operating conditions remain soft.
Negative Factors
Revenue ContractionRevenue has declined materially over several years, indicating that the core business is not currently expanding. Persistent top-line contraction can reduce operating leverage, constrain reinvestment, and make future earnings growth harder to sustain.

Utah Medical Products Key Performance Indicators (KPIs)

Revenue by Geography

$0.00$2.50M$5.00M$7.50M$10.00M$12.50MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26
Chart Insights
Data provided by:The Fly

Utah Medical Products (UTMD) vs. SPDR S&P 500 ETF (SPY)

-10%0%10%20%30%40%50%UTMD+36.44%SPY+11.73%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$205.19M
Dividend Yield
1.72%
Average Volume (3M)
36.33K
Price to Earnings (P/E)
21.4
Beta (1Y)
0.41
Revenue Growth
-9.62%
EPS Growth
-5.65%
Country
US
Employees
146
Sector
Healthcare
Sector Strength
51
Industry
Medical - Instruments & Supplies

Utah Medical Products Business Overview & Revenue Model

Company Description

Utah Medical Products, Inc. (UTMD) is a healthcare technology company focused on the creation, production, and supply of medical devices for the healthcare sector. UTMD offers a comprehensive portfolio of medical devices primarily serving labor and d...

Utah Medical Products Financial Statement Overview

Summary

The company's financial health is a tale of two cities. A fortress-like balance sheet with virtually no debt and excellent cash flow conversion (0.95x TTM) provides a strong foundation. However, this is offset by a persistent, multi-year decline in revenue and cash flows, indicating a shrinking business. The overall financial picture is that of a safe, well-managed, but contracting enterprise.

Income Statement

42Neutral

Balance Sheet

85Very Positive

Cash Flow

65Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue34.92M38.52M40.90M50.22M52.28M49.05M
Gross Profit20.14M22.00M24.14M30.04M32.20M30.92M
EBITDA14.87M17.06M19.65M24.75M27.74M26.34M
Net Income10.64M11.29M13.87M16.64M16.47M14.79M
Balance Sheet
Total Assets128.50M122.54M122.54M135.46M123.87M115.64M
Cash, Cash Equivalents and Short-Term Investments85.20M85.76M82.98M92.87M75.05M60.97M
Total Debt180.00K225.00K338.00K295.00K341.00K396.00K
Total Liabilities5.22M3.27M5.11M7.14M9.62M8.50M
Stockholders Equity123.28M119.27M117.43M128.31M114.25M107.14M
Cash Flow
Free Cash Flow10.86M14.32M14.60M21.64M20.33M20.65M
Operating Cash Flow11.47M14.69M14.83M22.28M21.15M21.20M
Investing Cash Flow-4.65M-371.00K-208.00K-639.00K-818.00K-552.00K
Financing Cash Flow-5.73M-12.34M-23.84M-4.17M-5.48M-10.90M

Utah Medical Products Technical Analysis

Technical Analysis SentimentNeutral
Last Price72.02

Price Trends

50DMA73.06Negative
100DMA71.66Positive
200DMA68.29Positive

Market Momentum

MACD-0.17Negative
RSI48.25Neutral
STOCH51.04Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTMD, the sentiment is Neutral. The current price of 72.02 is above the 20-day moving average (MA) of 71.97, below the 50-day MA of 73.06, and above the 200-day MA of 68.29, indicating a neutral trend. The MACD of -0.17 indicates Negative momentum. The RSI at 48.25 is Neutral, neither overbought nor oversold. The STOCH value of 51.04 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for UTMD.

Utah Medical Products Risk Analysis

Utah Medical Products disclosed 10 risk factors in its most recent earnings report. Utah Medical Products reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

Utah Medical Products Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

UTMD against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
MMSIMMSI71Outperform$5.06B31.499.65%―9.34%33.77%
ICUIICUI64Neutral$4.42B74.272.81%―-5.82%―
UTMDUTMD63Neutral$205.22M21.438.78%1.72%-9.62%-5.65%
BDXBDX63Neutral$58.68B52.054.64%1.85%-7.40%-28.89%
TFXTFX57Neutral$6.33B19.249.74%0.85%-29.30%―
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
RVPRVP50Neutral$16.92M-2.69-8.48%―0.12%5.16%

* Healthcare Sector Average

Performance Comparison

-20%0%20%40%UTMDBDXICUIMMSIRVPTFXDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
UTMD and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
UTMDUtah Medical Products72.0219.1436.19%
BDXBecton, Dickinson and Co215.4268.8146.94%
ICUIICU Medical176.9144.3433.45%
MMSIMerit Medical84.490.800.96%
RVPRetractable Technologies0.56-0.26-31.27%
TFXTeleflex159.5554.9252.49%

Utah Medical Products Corporate Events

Business Operations and StrategyFinancial DisclosuresM&A Transactions

Utah Medical Products Expands Via Orion Medical Acquisition

Positive
Aug 31, 2026

On August 31, 2026, Femcare Ltd., a wholly owned subsidiary of Utah Medical Products, Inc., completed the acquisition of all common shares of UK-based Orion Medical Supplies Ltd, a niche assembler and distributor of harm reduction medical device kits...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 14, 2026